Meloxicam Dosage for Acute Foot Pain
For acute foot pain in adults, start with meloxicam 7.5 mg once daily orally, which can be increased to 15 mg once daily if needed, with a maximum dose of 15 mg/day and treatment duration typically limited to 7-14 days.
Initial Dosing Strategy
The evidence supports starting with 7.5 mg once daily as the initial dose 1. This lower starting dose has demonstrated significant efficacy in acute pain conditions while minimizing adverse effects. Both 7.5 mg and 15 mg doses showed similar effectiveness compared to diclofenac 150 mg in acute sciatica trials 1.
Dose Escalation
If pain relief is inadequate after 2-3 days on 7.5 mg, increase to 15 mg once daily 1. The 15 mg dose remains the maximum recommended daily dose for acute conditions.
Route of Administration Options
For severe acute pain requiring rapid onset:
- Intramuscular (IM) route: 15 mg IM on day 1, followed by oral 15 mg daily for 7 days 2
- Intravenous (IV) route: 30 mg IV once daily for postoperative pain (though this formulation may have limited availability) 3
- IM meloxicam demonstrates significantly faster onset (30 minutes) compared to oral administration (60 minutes) 2, 4
The typical step-down approach involves IM administration for 3-5 days, then transition to oral 7.5-15 mg for 14 days 5, 6.
Treatment Duration
- Acute pain: 7-14 days is typically sufficient 1, 2
- Most patients achieve complete pain relief within 8-9 days 6
- Continue treatment only if clinically meaningful improvement occurs
- Reassess after 6 weeks; if no improvement, consider alternative diagnoses or referral 7
Important Clinical Considerations
Contraindications and cautions:
- Avoid in patients with active GI bleeding, severe renal impairment (eGFR <30), or cardiovascular disease
- Use with extreme caution in older adults (>65 years), who may require dose reduction 8
- Monitor for GI toxicity, renal function, and cardiovascular effects
- Consider acetaminophen as first-line therapy before NSAIDs, particularly in older patients 8
Predictors of better response:
- Age <65 years
- First episode of acute pain
- History of good response to NSAIDs 6
Predictors of poorer response requiring closer monitoring:
- Severe baseline pain (≥7/10)
- Pain at rest or nocturnal pain
- Radicular symptoms (sciatica pattern) 6
Combination Therapy
While some clinicians combine meloxicam with muscle relaxants or B vitamins 5, evidence does not demonstrate superior outcomes compared to NSAID monotherapy 6. Use meloxicam as monotherapy unless specific indications exist for adjunctive treatments.
Safety Profile
Meloxicam demonstrates favorable tolerability with adverse events occurring in approximately 4.6% of patients 6. GI side effects (nausea, constipation) are most common but occur less frequently than with traditional NSAIDs like diclofenac 2. The COX-2 preferential selectivity of meloxicam provides a better safety profile compared to non-selective NSAIDs.